Table 4.
Inhibitory effects of midkine-binding peptides on xenograft tumors
| Groups | n | Tumor weight (g) | Inhibitory rate (%) |
|---|---|---|---|
| PBS | 12 | 3.099 ± 0.452a | - |
| Control | 12 | 2.897 ± 0.316 | 6.5 |
| 5-FU 10 mg kg-1 | 12 | 1.692 ± 0.563* | 45.4 |
| MK-P1 0.5 mg kg-1 | 12 | 2.42 ± 0.56* | 22.0 |
| MK-P2 0.5 mg kg-1 | 12 | 2.31 ± 0.645* | 25.4 |
| MK-P3 0.5 mg kg-1 | 12 | 1.35 ± 0.88** | 56.4 |
| MK-P4 0.5 mg kg-1 | 12 | 2.31 ± 0.49* | 25.5 |
| MK-P5 0.5 mg kg-1 | 12 | 2.26 ± 0.34** | 27.0 |
| MK-P6 0.5 mg kg-1 | 12 | 2.50 ± 0.16* | 19.3 |
a
Data are presented as means (± SD), n = 12;
*
P < 0.05, compared with PBS control, the negative control group was treated with non-specific peptide;
**
P < 0.01, compared with PBS control, the negative control group was treated with non-specific peptide.